Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular miners find pain relief drugs from the sea

13.06.2005


A cone snail toxin discovered by Melbourne researchers has proven to have great potential for easing pain and could provide an improved treatment for neuropathic pain associated with diabetes.



Melbourne based company Metabolic Pharmaceuticals Limited recently announced successful results in preclinical trials of the toxin. The company will begin clinical trials in humans this month to firstly test the safety of the toxin in normal males, and later its effectiveness in treating the neuropathic pain associated with diabetes.

From the University of Melbourne’s Department of Biochemistry and Molecular Biology and the recently launched Bio21 Institute, Associate Professor Bruce Livett says the toxin – called ACV1 – also has potential for treating a range of other painful conditions, such as multiple sclerosis, shingles and sciatica.


“ACV1 has been shown to be effective in treating pain in several experimental animal models of human pain syndromes, including post-surgical and neuropathic pain,” Associate Professor Livett says.

“In addition, it has the unique property that it appears to accelerate the rate of recovery from a nerve injury.”

“We are very excited that clinical trials to test the effectiveness of ACV1 in humans with diabetic neuropathies will soon be underway and we expect that the potential of ACV1 in treating a range of other painful conditions will also be realised in time.”

ACV1 has shown potential for treating neuropathic pain, that is, pain generated inside the body (arising in the nervous system) as opposed to the other type of pain – nociceptive pain – which comes from the outside in, for example, a burn.

Associate Professor Livett says neuropathic pain is the most difficult form to treat and typically responds poorly to conventional painkillers such as morphine or aspirin. Other treatments have also been found to be largely ineffective.

The great potential of ACV1 is that eliminating neuropathic pain is where it works best.

Background

Associate Professor Livett and his colleagues first discovered ACV1 in 2003 while studying the toxins produced in the venom of Conus victoriae, a marine cone snail found in tropical waters off the coast of Australia.

All cone snails produce venom which they use to paralyse prey before killing and eating them. The venom of some cone snails is toxic to humans – as many as 30 people are known to have died from cone snail envenomation.

The cone snails that are dangerous to humans feed on fish by impaling them with a harpoon styled barb (a modified tooth called a radula) loaded with toxic venom.

Associate Professor Livett says there are up to 200 components in each venom and there are over 500 species of cone snail, each with a different cocktail of venom peptides. Fortunately, most cone snails hunt marine worms or other molluscs and are not harmful to humans.

It may seem unusual that toxic venoms can also be a source of pain relieving medication for humans.

Associate Professor Livett explains, “It appears that cone snails have adopted the general strategy of including a pain-reducing component among the more lethal components of its venom.”

“That is, it first pacifies its victim before immobilising and eventually killing it. Witnesses to cone snail envenomation report that death by cone snail poisoning is seemingly painless.”

It is this special pain-reducing component that the researchers have been interested in.

The Melbourne team, which includes Associate Professors Bruce Livett and Ken Gayler and Dr John Down from the Department of Biochemistry and Molecular Biology, Associate Professor Zeinab Khalil from the University’s National Ageing Research Institute, and research students Mr David Sandall, Mr David Keays and Ms Narmatha Satkunanathan, were the first to isolate and characterise ACV1.

It was a true collaborative venture starting with genes discovered by Associate Professor Gayler, Mr Sandall and Mr Keays, capitalizing on the pharmacological and chemical expertise of Associate Professor Livett and Dr Down, marrying with the physiological and pain assessment expertise of Associate Professor Khalil.

ACV1 is not the only therapeutic compound that cone snail venom has to offer. In fact, the venom is a cocktail of thousands of biologically active compounds of which only a few hundred have been identified.

Associate Professor Gayler says the team, by using genes as the starting point, are able to minimize the number of cone snails required to develop new tools and therapies for medical research and therefore minimise the environmental impact of the research. “With a single cone snail we can create and store large libraries of conotoxin genes.”

It was using this genetic mining technique that ACV1 was discovered – its peptide sequence was predicted solely from the DNA sequence. The peptide was then chemically synthesised in large quantities suitable for biological testing. This same approach is now being used by Metabolic Pharmaceuticals to synthesise gram amounts of ACV1 needed for the planned human clinical trials for diabetic neuropathy.

“With an increasing age demographic in our society the need for more effective pain suppressing compounds is a priority. ACV1 may fill this unmet need,” Associate Professor Livett says.

More information about this article:

Elaine Mulcahy
Media Promotions Officer
emulcahy@unimelb.edu.au
Tel: 61 3 8344 0181
Mob: 0421 641 506

Bruce Livett
Biochemistry and Molecular Biology
(03) 8344 2322
0403 010 477
b.livett@unimelb.edu.au

Chris Belyea
Metabolic Pharmaceuticals Ltd

Elaine Mulcahy | EurekAlert!
Further information:
http://www.metabolic.com.au
http://www.unimelb.edu.au

More articles from Life Sciences:

nachricht A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich

nachricht New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Switched-on DNA

20.02.2017 | Materials Sciences

Second cause of hidden hearing loss identified

20.02.2017 | Health and Medicine

Prospect for more effective treatment of nerve pain

20.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>